Pfiz­er ter­mi­nates PhI­II study of rare car­dio­vas­cu­lar drug picked up in $11.4B Ar­ray ac­qui­si­tion

While Pfiz­er’s $11.4 bil­lion ac­qui­si­tion of Ar­ray Bio­Phar­ma in the sum­mer of 2019 was main­ly fo­cused on on­col­o­gy, name­ly Braftovi and Mek­tovi, there were a few non-can­cer as­sets, in­clud­ing a Phase III drug be­ing test­ed in a rare car­dio­vas­cu­lar dis­ease.

The late-stage tri­al is now be­ing axed, along­side any fur­ther de­vel­op­ment of the oral small mol­e­cule, the phar­ma gi­ant dis­closed af­ter the clos­ing bell on Wednes­day. Based on an in­ter­im fu­til­i­ty analy­sis of the glob­al Phase III REALM-DCM tri­al, Pfiz­er de­ter­mined a path for­ward was not in its best in­ter­est. Pfiz­er no longer ex­pect­ed the study would meet its pri­ma­ry goal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.